Bio Roundup: Mylan Grilled, Duchenne Kids Thrilled, Zuck-Chan & More
Xconomy
SEPTEMBER 23, 2016
Allergan also bought Akarna Therapeutics, another NASH drug developer, for a much smaller sum. —Roche’s Genentech division is paying Germany’s BioNTech $310 million in upfront and near-term milestones to co-develop cancer vaccines. based skin drug developer Novan (NASDAQ: NOVN ) raised $45 million in its IPO.
Let's personalize your content